Regents of the University of California

Regents of the University of California was paid $264.99M by Medicaid between Jan 2018 and Dec 2024, across 890 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 9.1% of everything it billed.

33Billing provider infoREGENTS OF THE UNIVERSITY OF CALIFORNIA
SAN DIEGO, CA 92103

33aNPI1184722779assigned 09/20/2006

33bProvider typeCardiac Rehabilitation Clinic/Center

28Total paid$264.99M

24GClaims4,174,520

24DCodes billed890

24AFirst – last monthJan 2018 – Dec 2024

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	570,372	$35.22M
2019	632,316	$42.13M
2020	530,840	$41.98M
2021	553,419	$38.31M
2022	625,011	$39.31M
2023	643,648	$33.10M
2024incomplete	618,914	$34.94M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J9271	Injection, pembrolizumab, 1 mg	9.1%	6,235	2,239	$24.20M
77386		7.5%	19,248	1,822	$19.85M
J9299	Injection, nivolumab, 1 mg	3.9%	3,997	1,299	$10.44M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3.6%	2,275	1,989	$9.63M
J2505	Injection, pegfilgrastim, 6 mg	3.2%	1,996	1,361	$8.59M
0510		2.7%	206,116	174,710	$7.11M
78815	Positron emission tomography (PET) for limited area imaging	2.6%	4,605	4,537	$6.82M
J3380	Injection, vedolizumab, intravenous, 1 mg	2.4%	3,712	1,060	$6.42M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	2.1%	1,540	988	$5.64M
J9035	Injection, bevacizumab, 10 mg	2.1%	2,551	987	$5.57M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.5%	19,628	19,168	$4.06M
J2357	Injection, omalizumab, 5 mg	1.4%	2,280	1,368	$3.63M

878 more codes

0450	Emergency room services	1.4%	51,728	$3.63M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	1.2%	97,761	$3.23M
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	1.2%	2,465	$3.14M
J2323	Injection, natalizumab, 1 mg	1.2%	2,534	$3.13M
J0897	Injection, denosumab, 1 mg	1.2%	2,838	$3.11M
71260	Computed tomography, thorax, diagnostic; with contrast material	1.1%	16,083	$2.87M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	1.1%	6,665	$2.85M
J3490	Unclassified drugs	1.1%	127,918	$2.82M
80053	Comprehensive metabolic panel	1.0%	244,457	$2.68M
J9312	Injection, rituximab, 10 mg	<1%	739	$2.53M
J9306	Injection, pertuzumab, 1 mg	<1%	2,186	$2.48M
99283	Emergency room visit (moderate)	<1%	34,374	$2.42M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	31,147	$2.22M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	9,713	$2.15M
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	561	$2.12M
96375	Therapeutic injection; each additional sequential IV push	<1%	35,662	$1.89M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	33,551	$1.81M
99499		<1%	23,819	$1.75M
74183		<1%	4,721	$1.74M
J9202	Goserelin acetate implant, per 3.6 mg	<1%	2,242	$1.73M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	275,328	$1.69M
77387		<1%	4,186	$1.62M
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	<1%	1,058	$1.57M
0760		<1%	42,103	$1.48M
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	54,629	$1.46M
J9310	Injection, rituximab, 100 mg	<1%	415	$1.43M
72197		<1%	3,696	$1.40M
J9022	Injection, atezolizumab, 10 mg	<1%	324	$1.38M
77301		<1%	1,537	$1.38M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	22,738	$1.33M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	18,395	$1.28M
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	592	$1.24M
0360		<1%	7,671	$1.19M
77412		<1%	15,816	$1.09M
99285	Emergency room visit (most serious)	<1%	5,877	$1.07M
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	4,716	$1.06M
99284	Emergency room visit (serious)	<1%	7,180	$1.05M
70450	Computed tomography, head or brain; without contrast material	<1%	8,381	$1.04M
99199	Unlisted special service, procedure or report	<1%	22,484	$1.03M
87536		<1%	17,768	$1.03M
0762		<1%	1,081	$1.01M
71250		<1%	7,379	$983K
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	476	$983K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	26,713	$937K
J9316	Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg	<1%	196	$901K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	<1%	441	$881K
Q3014	Telehealth originating site facility fee	<1%	43,093	$856K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	6,794	$839K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	11,817	$813K
97139		<1%	28,868	$785K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	22,258	$757K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	22,262	$752K
93970		<1%	4,213	$736K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	11,539	$694K
77066	Tomosynthesis, mammo	<1%	5,963	$686K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	29,744	$674K
J1453	Injection, fosaprepitant, 1 mg	<1%	7,687	$671K
96361	Intravenous infusion, hydration; each additional hour	<1%	19,501	$667K
77334		<1%	2,930	$659K
77049		<1%	1,485	$639K
72125	Computed tomography, cervical spine; without contrast material	<1%	3,668	$628K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	2,035	$622K
97750		<1%	12,058	$619K
87507		<1%	1,884	$612K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	2,645	$591K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	1,342	$584K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	5,960	$577K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	5,399	$575K
86480		<1%	15,734	$560K
77300		<1%	2,781	$547K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	13,424	$518K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	8,397	$517K
77336		<1%	8,190	$516K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	2,330	$513K
76830	Ultrasound, transvaginal	<1%	5,781	$500K
70486		<1%	2,771	$496K
74178		<1%	1,985	$496K
84443	Thyroid stimulating hormone (TSH)	<1%	44,267	$487K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	10,302	$487K
71275	Computed tomographic angiography, chest, with contrast material	<1%	2,459	$485K
71046	Radiologic examination, chest; 2 views	<1%	18,754	$466K
59025	Fetal non-stress test	<1%	14,783	$459K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	<1%	136	$449K
86360		<1%	14,268	$448K
72141		<1%	1,837	$446K
93975		<1%	2,526	$446K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	7,370	$437K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	7,627	$433K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	5,208	$432K
87497		<1%	10,426	$420K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	3,447	$417K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	4,557	$413K
96417		<1%	8,135	$411K
70491		<1%	2,264	$400K
96415		<1%	9,016	$394K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	2,790	$392K
77295		<1%	836	$389K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	1,430	$387K
J9395	Injection, fulvestrant, 25 mg	<1%	559	$386K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	2,243	$372K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	1,394	$370K
76642		<1%	5,620	$364K
G0422	Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session	<1%	4,542	$362K
A9585	Injection, gadobutrol, 0.1 ml	<1%	17,887	$359K
77338		<1%	1,650	$357K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	46,295	$356K
97597		<1%	8,433	$350K
76801		<1%	5,090	$346K
96367		<1%	7,670	$345K
72156		<1%	658	$341K
83735		<1%	50,291	$335K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	1,147	$334K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	18,399	$330K
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	<1%	124	$329K
0250		<1%	19,437	$326K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,199	$323K
88185		<1%	1,711	$320K
J9173	Injection, durvalumab, 10 mg	<1%	55	$309K
76770		<1%	4,461	$306K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	16,443	$299K
97799		<1%	12,352	$299K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	2,985	$293K
76813		<1%	4,146	$289K
93351		<1%	1,661	$288K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	703	$288K
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	3,849	$283K
80197		<1%	22,617	$281K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	3,860	$280K
93325		<1%	2,345	$274K
86832		<1%	7,045	$273K
99214	Doctor's office visit, returning patient (more involved)	<1%	6,786	$269K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	7,060	$268K
94729		<1%	6,662	$265K
95913		<1%	901	$259K
86833		<1%	6,812	$259K
94726		<1%	5,753	$255K
86803		<1%	20,557	$252K
81001		<1%	73,497	$243K
83036	Hemoglobin; glycosylated (A1C)	<1%	37,838	$242K
80061	Lipid panel	<1%	30,741	$240K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	4,327	$239K
82728		<1%	20,522	$239K
99234		<1%	8,705	$237K
88341		<1%	2,237	$235K
87086	Culture, bacterial; quantitative colony count, urine	<1%	34,310	$232K
G0423	Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session	<1%	2,883	$229K
71045	Radiologic examination, chest; single view	<1%	14,960	$215K
80048	Basic metabolic panel (calcium, ionized)	<1%	32,928	$215K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	4,066	$214K
78306		<1%	1,563	$214K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	2,346	$212K
93971		<1%	2,295	$211K
96416		<1%	2,871	$203K
90715		<1%	4,953	$203K
0710		<1%	6,686	$203K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	3,035	$198K
77290		<1%	1,225	$193K
72158		<1%	424	$191K
77065	Tomosynthesis, mammo	<1%	2,177	$189K
83880		<1%	10,094	$189K
76819	Fetal biophysical profile; without non-stress testing	<1%	3,122	$188K
77062		<1%	4,427	$188K
Z7502		<1%	5,042	$188K
J9070	Cyclophosphamide, 100 mg	<1%	701	$187K
76536		<1%	2,774	$184K
90651		<1%	706	$183K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	1,650	$182K
90677		<1%	770	$180K
72131		<1%	1,201	$176K
86900		<1%	26,129	$175K
90750		<1%	1,242	$172K
70543		<1%	440	$171K
0270		<1%	19,401	$170K
81329		<1%	2,385	$170K
73610		<1%	5,100	$170K
77373		<1%	183	$169K
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	<1%	144	$169K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	5,307	$168K
70496		<1%	847	$167K
72157		<1%	279	$166K
93880		<1%	1,575	$166K
Q5114	Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg	<1%	88	$165K
93458		<1%	197	$164K
99152		<1%	3,819	$164K
86003		<1%	2,297	$163K
96402		<1%	5,370	$162K
73630		<1%	5,462	$161K
0370		<1%	2,786	$160K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	1,231	$158K
72100		<1%	6,079	$158K
92557		<1%	2,402	$155K
83970		<1%	6,888	$153K
84484		<1%	14,797	$150K
73130		<1%	4,345	$150K
95886		<1%	2,578	$148K
86780		<1%	17,158	$147K
94010		<1%	7,041	$147K
73110		<1%	4,188	$146K
73221		<1%	383	$146K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	124	$146K
97598		<1%	885	$146K
73502		<1%	5,227	$145K
86850		<1%	24,417	$145K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	468	$145K
82107		<1%	4,683	$142K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	6,707	$141K
Z7500		<1%	4,409	$141K
82784		<1%	12,135	$140K
99215	Doctor's office visit, returning patient (complex)	<1%	2,382	$140K
97802		<1%	2,179	$138K
90686		<1%	6,500	$137K
87522	Neg quan hep c or qual rna	<1%	4,442	$137K
87340		<1%	13,615	$135K
J0185	Injection, aprepitant, 1 mg	<1%	1,063	$134K
J2785	Injection, regadenoson, 0.1 mg	<1%	967	$131K
90734		<1%	1,151	$131K
93320		<1%	1,406	$129K
87799		<1%	4,342	$128K
70498		<1%	680	$128K
96523		<1%	2,114	$127K
84439		<1%	17,681	$125K
82378		<1%	8,822	$125K
73030		<1%	4,542	$124K
73562		<1%	4,009	$118K
82607		<1%	12,007	$117K
74246		<1%	1,062	$117K
99221		<1%	2,662	$115K
84100		<1%	36,271	$115K
83951		<1%	3,544	$115K
85610		<1%	32,952	$113K
J9354	Injection, ado-trastuzumab emtansine, 1 mg	<1%	38	$112K
94060		<1%	2,581	$112K
77080		<1%	2,560	$109K
83550		<1%	16,149	$108K
76942		<1%	2,487	$108K
83615		<1%	27,615	$107K
88342		<1%	3,535	$106K
J2704	Injection, propofol, 10 mg	<1%	15,194	$106K
87088		<1%	18,290	$105K
G0378	Hospital observation service, per hour	<1%	2,501	$103K
83540		<1%	17,559	$102K
84403		<1%	6,432	$102K
82570		<1%	23,853	$102K
91010		<1%	1,995	$101K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	1,165	$101K
86235		<1%	2,499	$101K
82533		<1%	7,716	$100K
77063	Screening digital breast tomosynthesis, bilateral	<1%	4,458	$99K
85027		<1%	20,316	$98K
86901		<1%	25,722	$98K
87077		<1%	17,126	$97K
82248		<1%	23,635	$96K
36415	Collection of venous blood by venipuncture	<1%	38,511	$95K
88112		<1%	3,012	$95K
73560		<1%	4,244	$93K
J9045	Injection, carboplatin, 50 mg	<1%	2,478	$93K
87480		<1%	5,581	$92K
84153		<1%	7,601	$92K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	1,227	$92K
90732		<1%	920	$92K
87186		<1%	13,864	$91K
99204	Doctor's office visit, new patient (more involved)	<1%	1,273	$91K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	2,868	$91K
86923		<1%	1,671	$90K
97165		<1%	1,692	$90K
87510		<1%	5,513	$90K
84702		<1%	6,043	$90K
J9267	Injection, paclitaxel, 1 mg	<1%	4,464	$89K
93925		<1%	1,233	$88K
90670		<1%	473	$88K
78264		<1%	294	$88K
72040		<1%	2,986	$87K
97163		<1%	1,672	$87K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,733	$86K
86160		<1%	4,990	$86K
91037		<1%	1,680	$86K
86706		<1%	8,089	$85K
88307		<1%	1,369	$85K
81513		<1%	1,451	$84K
83690		<1%	13,621	$84K
87660		<1%	5,577	$84K
74174		<1%	315	$83K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	65	$83K
96376		<1%	4,094	$82K
97161		<1%	2,267	$81K
77059		<1%	133	$80K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,303	$79K
87653		<1%	3,701	$78K
Z9725		<1%	2,576	$77K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	16,119	$77K
86704		<1%	6,462	$77K
97803		<1%	2,220	$76K
86140		<1%	19,448	$75K
85730		<1%	14,828	$74K
88142		<1%	7,875	$74K
87517		<1%	2,614	$74K
97166		<1%	1,680	$74K
96411		<1%	2,634	$73K
J9171	Injection, docetaxel, 1 mg	<1%	649	$73K
82746		<1%	6,312	$73K
82670		<1%	3,089	$72K
99213	Doctor's office visit, returning patient (routine)	<1%	2,725	$72K
80076		<1%	10,628	$72K
88184		<1%	1,680	$71K
93976		<1%	510	$71K
20610		<1%	2,924	$71K
72050		<1%	1,191	$70K
86300		<1%	5,440	$70K
93017		<1%	1,455	$69K
94621		<1%	646	$69K
J9206	Injection, irinotecan, 20 mg	<1%	1,703	$68K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	376	$67K
93356		<1%	1,761	$64K
86334		<1%	4,389	$64K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,232	$63K
72082		<1%	1,401	$63K
A9581	Injection, gadoxetate disodium, 1 ml	<1%	764	$62K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	10,391	$62K
73700		<1%	385	$62K
84156		<1%	19,540	$62K
70480		<1%	271	$61K
83883		<1%	5,861	$59K
J3489	Injection, zoledronic acid, 1 mg	<1%	1,441	$59K
99203	Doctor's office visit, new patient (routine)	<1%	979	$59K
93296		<1%	2,325	$58K
99497		<1%	1,026	$57K
81335		<1%	676	$57K
83021		<1%	4,682	$57K
86787		<1%	5,475	$56K
72110		<1%	1,125	$56K
87481		<1%	1,967	$56K
73590		<1%	2,192	$55K
J2796	Injection, romiplostim, 10 micrograms	<1%	43	$53K
76870		<1%	884	$53K
73120		<1%	1,090	$52K
99205	Prolong outpt/office vis	<1%	614	$52K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,460	$52K
96377		<1%	1,574	$51K
96401		<1%	2,096	$50K
72070		<1%	1,968	$50K
A9520	Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries	<1%	154	$50K
85652		<1%	19,050	$48K
81408		<1%	274	$48K
86762		<1%	4,390	$47K
J1170	Injection, hydromorphone, up to 4 mg	<1%	7,189	$47K
86038		<1%	4,189	$46K
86225		<1%	3,836	$46K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	11,027	$46K
87040		<1%	3,680	$46K
82962		<1%	10,483	$46K
62323		<1%	304	$46K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	345	$46K
96409		<1%	1,756	$45K
96368		<1%	2,118	$45K
70544		<1%	203	$45K
82550		<1%	8,827	$45K
99070		<1%	7,302	$45K
90746		<1%	668	$44K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	2,653	$44K
74018		<1%	2,322	$44K
81025		<1%	7,432	$44K
72146		<1%	180	$43K
74221		<1%	529	$43K
84270		<1%	3,432	$43K
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	<1%	929	$42K
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	<1%	150	$42K
78195		<1%	214	$42K
93922		<1%	1,261	$42K
93505		<1%	33	$42K
84165		<1%	5,377	$41K
86902		<1%	849	$40K
99244	Office or other outpatient consultation, moderate to high complexity	<1%	399	$40K
73080		<1%	1,036	$40K
83605		<1%	4,230	$39K
99153	Mod sedat endo service >5yrs	<1%	2,112	$39K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	990	$39K
92567		<1%	1,437	$39K
J9190	Injection, fluorouracil, 500 mg	<1%	2,172	$39K
87070		<1%	6,647	$39K
95912		<1%	272	$38K
91065		<1%	1,374	$38K
86304		<1%	3,241	$38K
82977		<1%	5,964	$37K
0700		<1%	630	$37K
73552		<1%	1,648	$37K
82553		<1%	4,270	$36K
86301		<1%	2,737	$36K
83001		<1%	2,431	$36K
82805		<1%	1,147	$36K
77470		<1%	347	$36K
99417	Prolong home eval add 15m	<1%	1,055	$35K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	2,073	$35K
76820		<1%	962	$34K
86708		<1%	2,784	$34K
73564		<1%	888	$34K
75574		<1%	200	$34K
86355		<1%	1,490	$33K
94618		<1%	1,357	$33K
72170		<1%	1,319	$32K
83516		<1%	3,134	$32K
82105		<1%	2,254	$32K
81283		<1%	471	$31K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	15,097	$31K
97010		<1%	735	$31K
84550		<1%	9,838	$30K
74160		<1%	125	$30K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	13,725	$30K
31231		<1%	1,286	$29K
86255		<1%	2,456	$29K
91200		<1%	566	$29K
80195		<1%	3,717	$29K
52000		<1%	494	$29K
77061		<1%	762	$28K
84146		<1%	1,731	$28K
31575		<1%	569	$28K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	13,517	$28K
92610		<1%	887	$28K
0942		<1%	416	$28K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	5,856	$27K
L4360	Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	<1%	122	$27K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	3,281	$27K
84480		<1%	2,557	$27K
86769		<1%	802	$27K
0761		<1%	870	$26K
36430		<1%	328	$26K
86147		<1%	1,155	$26K
86665		<1%	864	$26K
73090		<1%	1,010	$25K
82951		<1%	2,206	$25K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	6,737	$25K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	<1%	13	$25K
86593		<1%	6,826	$24K
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	1,467	$24K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	289	$24K
80158		<1%	2,170	$24K
77332		<1%	646	$24K
81406		<1%	712	$24K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	761	$24K
86039		<1%	2,307	$23K
J9000	Injection, doxorubicin hydrochloride, 10 mg	<1%	244	$23K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	4,501	$23K
77417		<1%	779	$23K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	1,405	$23K
85379		<1%	2,519	$23K
0914		<1%	823	$23K
43235		<1%	230	$22K
82785		<1%	2,076	$22K
86870		<1%	779	$22K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	8,978	$22K
77280		<1%	326	$22K
97116		<1%	879	$21K
83520		<1%	2,130	$21K
J1644	Injection, heparin sodium, per 1000 units	<1%	3,718	$21K
82043		<1%	6,167	$21K
J0690	Injection, cefazolin sodium, 500 mg	<1%	3,865	$21K
43259		<1%	204	$21K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	3,235	$21K
87116		<1%	3,262	$21K
82610		<1%	3,093	$21K
86705		<1%	1,686	$21K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,285	$20K
87081		<1%	4,163	$20K
0521		<1%	597	$20K
81370		<1%	41	$20K
82565		<1%	5,196	$20K
86644		<1%	1,598	$19K
71271		<1%	204	$19K
J1756	Injection, iron sucrose, 1 mg	<1%	685	$19K
87486		<1%	776	$19K
87015		<1%	3,997	$18K
86825		<1%	149	$18K
87581		<1%	761	$18K
J2560	Injection, phenobarbital sodium, up to 120 mg	<1%	349	$17K
87102		<1%	2,719	$17K
78816		<1%	12	$17K
J0485	Injection, belatacept, 1 mg	<1%	59	$17K
J9060	Injection, cisplatin, powder or solution, 10 mg	<1%	893	$17K
88313		<1%	712	$17K
81226		<1%	605	$17K
83002		<1%	1,101	$17K
93299		<1%	379	$17K
76391		<1%	68	$16K
81401		<1%	876	$16K
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	2,520	$16K
73060		<1%	717	$16K
88304		<1%	917	$16K
87493		<1%	1,209	$16K
82150		<1%	3,405	$16K
27500		<1%	74	$16K
77073		<1%	757	$15K
86146		<1%	554	$15K
86356		<1%	244	$15K
87205		<1%	5,606	$15K
90662		<1%	697	$15K
V2632	Posterior chamber intraocular lens	<1%	181	$15K
86431		<1%	2,455	$15K
49083		<1%	386	$14K
99238	Hospital discharge day management, 30 minutes or less	<1%	418	$14K
87338		<1%	1,506	$14K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	98	$14K
85045		<1%	4,159	$14K
80069		<1%	2,318	$14K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,064	$14K
72128		<1%	95	$14K
76825		<1%	114	$13K
81206		<1%	255	$13K
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	288	$13K
82803		<1%	1,120	$13K
76882		<1%	270	$13K
90636		<1%	129	$13K
86635		<1%	1,474	$13K
73620		<1%	193	$13K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	2,830	$12K
87206		<1%	3,243	$12K
91320		<1%	167	$12K
95911		<1%	104	$11K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	570	$11K
86200		<1%	1,647	$11K
94799		<1%	525	$11K
0681		<1%	29	$11K
81225		<1%	605	$11K
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	<1%	340	$11K
82950		<1%	2,608	$11K
L3908	Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf	<1%	177	$11K
86141		<1%	1,147	$11K
92611		<1%	374	$11K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	36	$11K
81455		<1%	12	$10K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	265	$10K
82310		<1%	1,653	$10K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	2,039	$10K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	1,160	$10K
93926		<1%	168	$10K
73140		<1%	559	$10K
82103		<1%	1,323	$10K
88271		<1%	435	$10K
73070		<1%	370	$10K
46600		<1%	838	$9K
76881		<1%	108	$9K
87075		<1%	1,391	$9K
P9047	Infusion, albumin (human), 25%, 50 ml	<1%	38	$9K
64615		<1%	277	$9K
73720		<1%	25	$9K
85613		<1%	683	$9K
96111		<1%	85	$9K
83993		<1%	779	$9K
92612		<1%	79	$8K
86645		<1%	494	$8K
86800		<1%	1,430	$8K
84134		<1%	892	$8K
86703		<1%	675	$8K
92550		<1%	467	$8K
90739		<1%	157	$8K
81405		<1%	205	$8K
36561		<1%	93	$8K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	904	$8K
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	278	$8K
84432		<1%	977	$8K
84425		<1%	1,513	$8K
82232		<1%	858	$8K
36416		<1%	1,998	$8K
86835		<1%	85	$7K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	226	$7K
81230		<1%	610	$7K
99231	Subsequent hospital care, per day, straightforward or low complexity	<1%	125	$7K
90632		<1%	115	$7K
81231		<1%	612	$7K
94664		<1%	747	$7K
82330		<1%	815	$7K
81328		<1%	514	$7K
81232		<1%	517	$7K
77091		<1%	362	$7K
73200		<1%	38	$7K
81227		<1%	604	$6K
82274		<1%	1,119	$6K
86828		<1%	111	$6K
86945		<1%	207	$6K
82390		<1%	568	$6K
84460		<1%	1,465	$6K
78830		<1%	26	$6K
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	<1%	203	$6K
87529		<1%	185	$6K
85660		<1%	618	$6K
74170		<1%	13	$6K
76827		<1%	74	$6K
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	305	$6K
86765		<1%	654	$6K
90656		<1%	329	$6K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	101	$6K
J0461	Injection, atropine sulfate, 0.01 mg	<1%	1,249	$6K
20553		<1%	460	$6K
84450		<1%	1,357	$6K
51700		<1%	336	$6K
82947		<1%	1,940	$6K
88346		<1%	143	$6K
C1781	Mesh (implantable)	<1%	13	$5K
97162		<1%	99	$5K
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	33	$5K
J1071	Injection, testosterone cypionate, 1 mg	<1%	1,363	$5K
87631		<1%	87	$5K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	581	$5K
29705		<1%	486	$5K
80164		<1%	467	$5K
75561		<1%	28	$5K
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	1,200	$5K
83010		<1%	644	$5K
G0008	Administration of influenza virus vaccine	<1%	938	$5K
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	1,311	$5K
76376		<1%	114	$5K
90480		<1%	409	$4K
85384		<1%	569	$4K
86790		<1%	501	$4K
84520		<1%	1,492	$4K
84436		<1%	590	$4K
J7030	Infusion, normal saline solution , 1000 cc	<1%	894	$4K
93226		<1%	89	$4K
88312		<1%	299	$4K
J1815	Injection, insulin, per 5 units	<1%	1,473	$4K
81376		<1%	58	$4K
86880		<1%	534	$4K
0272		<1%	675	$4K
80187		<1%	264	$4K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,069	$4K
J0780	Injection, prochlorperazine, up to 10 mg	<1%	424	$4K
86777		<1%	319	$4K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	200	$4K
90694		<1%	244	$4K
16020		<1%	79	$4K
0301		<1%	120	$4K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	376	$4K
82104		<1%	609	$4K
72190		<1%	57	$4K
81003		<1%	2,093	$4K
95887		<1%	72	$4K
93319		<1%	48	$4K
86709		<1%	347	$4K
92526		<1%	219	$4K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	13	$4K
83695		<1%	570	$3K
71020		<1%	138	$3K
87305		<1%	569	$3K
62321		<1%	13	$3K
L3260	Surgical boot/shoe, each	<1%	112	$3K
73521		<1%	100	$3K
81268		<1%	20	$3K
86376		<1%	287	$3K
94625		<1%	132	$3K
82024		<1%	335	$3K
81355		<1%	502	$3K
83921		<1%	461	$3K
73000		<1%	131	$3K
94727		<1%	124	$3K
86778		<1%	233	$3K
86677		<1%	277	$3K
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	<1%	709	$3K
51798		<1%	254	$3K
Z7610		<1%	2,803	$3K
81241		<1%	609	$3K
99217		<1%	27	$3K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	28	$3K
86256		<1%	279	$3K
87899		<1%	535	$3K
74182		<1%	13	$3K
J2060	Injection, lorazepam, 2 mg	<1%	1,733	$3K
84300		<1%	752	$3K
81404		<1%	188	$3K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	784	$3K
81240		<1%	612	$3K
81291		<1%	611	$3K
99429		<1%	181	$3K
93798		<1%	120	$2K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	426	$2K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	109	$2K
93750		<1%	63	$2K
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	780	$2K
10060		<1%	88	$2K
A9609	Fludeoxyglucose f18 up to 15 millicuries	<1%	63	$2K
82525		<1%	356	$2K
90472	Immunization administration, each additional vaccine (list separately)	<1%	291	$2K
29581		<1%	114	$2K
J9075	Injection, cyclophosphamide, not otherwise specified, 5 mg	<1%	43	$2K
82140		<1%	195	$2K
J1940	Injection, furosemide, up to 20 mg	<1%	424	$2K
J1626	Injection, granisetron hydrochloride, 100 mcg	<1%	375	$2K
Q9968	Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg	<1%	15	$2K
88173		<1%	54	$2K
81402		<1%	203	$2K
81002		<1%	931	$2K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	577	$2K
87999		<1%	21	$2K
97014		<1%	92	$2K
C1769	Guide wire	<1%	355	$2K
86364		<1%	133	$2K
87901		<1%	12	$2K
76981		<1%	36	$2K
84630		<1%	338	$2K
36591		<1%	187	$2K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	72	$2K
93990		<1%	26	$2K
82952		<1%	473	$2K
84132		<1%	730	$2K
95816		<1%	39	$2K
87506		<1%	13	$2K
74220		<1%	55	$2K
92504		<1%	116	$2K
90740		<1%	13	$2K
82075		<1%	86	$2K
J3480	Injection, potassium chloride, per 2 meq	<1%	1,452	$2K
92015	Determination of refractive state	<1%	170	$2K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	264	$2K
84145		<1%	157	$2K
95872		<1%	26	$2K
86834		<1%	14	$2K
86696		<1%	100	$2K
97535	Self-care/home management training, each 15 minutes	<1%	82	$1K
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	32	$1K
74230		<1%	52	$1K
76999		<1%	33	$1K
A9577	Injection, gadobenate dimeglumine (multihance), per ml	<1%	41	$1K
87210		<1%	175	$1K
84133		<1%	406	$1K
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	927	$1K
92522		<1%	14	$1K
J1790	Injection, droperidol, up to 5 mg	<1%	252	$1K
93225		<1%	46	$1K
86015		<1%	272	$1K
82077		<1%	65	$1K
87420		<1%	173	$1K
82040		<1%	528	$1K
82436		<1%	336	$1K
84157		<1%	432	$1K
86695		<1%	100	$1K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	274	$1K
95910		<1%	14	$1K
88237		<1%	31	$1K
91322		<1%	94	$1K
87806		<1%	51	$1K
86922		<1%	36	$1K
99245		<1%	12	$1K
29125		<1%	26	$1K
87900		<1%	13	$1K
87181		<1%	957	$1K
89051		<1%	396	$1K
0064A		<1%	46	$1K
76937		<1%	57	$1K
92134		<1%	42	$1K
87906		<1%	12	$1K
97755		<1%	42	$982.80
80177		<1%	165	$958.65
84238		<1%	120	$935.06
J3370	Injection, vancomycin hcl, 500 mg	<1%	92	$932.30
81400		<1%	197	$923.56
86753		<1%	126	$913.98
51784		<1%	41	$912.18
72080		<1%	31	$903.69
J1250	Injection, dobutamine hydrochloride, per 250 mg	<1%	115	$900.85
76821		<1%	17	$898.96
90674		<1%	53	$885.63
69210		<1%	82	$853.84
A0429	Emergency ambulance ride, basic life support	<1%	41	$846.76
0390		<1%	58	$839.10
J2175	Injection, meperidine hydrochloride, per 100 mg	<1%	1,333	$821.66
87209		<1%	76	$807.69
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	17	$803.82
J1630	Injection, haloperidol, up to 5 mg	<1%	267	$802.48
86735		<1%	92	$785.55
82810		<1%	79	$763.15
92083		<1%	67	$758.54
87252		<1%	33	$736.49
84144		<1%	38	$724.91
C1726	Catheter, balloon dilatation, non-vascular	<1%	26	$705.21
82747		<1%	68	$677.84
82239		<1%	77	$645.35
83090		<1%	63	$644.59
75571		<1%	14	$639.66
88311		<1%	166	$626.71
87385		<1%	70	$623.30
X3920		<1%	12	$599.64
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	202	$596.07
J2305	Injection, nitroglycerin, 5 mg	<1%	88	$585.02
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	26	$576.35
51702		<1%	27	$563.89
20611		<1%	13	$553.20
Q9965	Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml	<1%	78	$538.81
84207		<1%	121	$532.82
0134A		<1%	48	$524.13
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	250	$522.99
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	15	$517.80
87184		<1%	141	$506.35
84182		<1%	36	$499.47
0124A		<1%	30	$489.76
81050		<1%	372	$477.03
J9370	Vincristine sulfate, 1 mg	<1%	34	$460.54
87400		<1%	49	$450.26
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	27	$432.97
85347		<1%	45	$400.86
84445		<1%	24	$392.08
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	212	$389.05
85300		<1%	38	$376.50
86592		<1%	127	$374.01
20550		<1%	13	$355.90
80178		<1%	54	$355.53
88300		<1%	52	$350.65
95885		<1%	12	$349.99
87350		<1%	42	$346.46
99195		<1%	16	$339.73
84590		<1%	84	$333.45
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	174	$294.71
J2550	Injection, promethazine hcl, up to 50 mg	<1%	190	$290.39
82375		<1%	14	$284.57
86036		<1%	19	$282.19
86682		<1%	25	$279.16
88275		<1%	15	$277.25
97804		<1%	12	$258.48
88274		<1%	28	$257.45
27096		<1%	14	$240.94
84305		<1%	37	$223.84
84295		<1%	85	$220.08
80175		<1%	50	$216.47
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	22	$212.07
90785		<1%	182	$195.99
A9540	Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries	<1%	13	$181.16
J1171	Injection, hydromorphone, 0.1 mg	<1%	28	$180.81
82668		<1%	31	$177.25
80156		<1%	13	$176.79
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	<1%	127	$158.40
94760		<1%	18	$154.78
83721		<1%	41	$154.59
88108		<1%	14	$154.48
85007		<1%	26	$147.10
J1580	Injection, garamycin, gentamicin, up to 80 mg	<1%	26	$136.45
87427		<1%	16	$133.83
84446		<1%	29	$130.06
82787		<1%	12	$128.55
94644		<1%	12	$121.90
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	<1%	69	$112.08
87449		<1%	16	$111.64
85018		<1%	70	$111.39
85014		<1%	44	$99.59
84478		<1%	18	$98.82
C1889	Implantable/insertable device, not otherwise classified	<1%	240	$97.22
84080		<1%	24	$94.76
85303		<1%	12	$94.71
J7120	Ringers lactate infusion, up to 1000 cc	<1%	16	$92.59
87045		<1%	16	$83.22
85651		<1%	40	$82.10
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	14	$70.00
82960		<1%	12	$61.97
86707		<1%	12	$57.85
86308		<1%	12	$54.53
86352		<1%	18	$54.34
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	235	$51.30
85732		<1%	12	$49.91
83935		<1%	14	$46.90
0305		<1%	28	$43.65
84075		<1%	13	$41.02
E0114	Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips	<1%	12	$29.00
84155		<1%	16	$26.31
87046		<1%	16	$25.79
0306		<1%	29	$20.07
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg	<1%	41	$17.65
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	<1%	13	$16.64
J0153	Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)	<1%	12	$16.27
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	224	$15.07
0324		<1%	13	$11.24
0255		<1%	51	$10.88
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes)	<1%	32	$4.12
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	<1%	21	$2.38
J8540	Dexamethasone, oral, 0.25 mg	<1%	17	$0.95
Q0247	Injection, sotrovimab, 500 mg	<1%	29	$0.02
91306		0%	47	$0.00
0300		0%	12	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	236	$0.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	236	$0.00
91300		0%	12	$0.00
A4565	Slings	0%	40	$0.00
91313		0%	19	$0.00
A4649	Surgical supply; miscellaneous	0%	37	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDONALDSON, LORI (CFO)

Same official

Other billing entities under DONALDSON, LORI

Full network →

Provider	Location	Paid
Regents of the University of California	San Diego, CA	$7.28M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.